On September 21, LEADS BIOLABS-B rose 5.29% in regular trading, trading at 58.8 HKD/share, with turnover of approximately 22.61 million HKD. The stock extended its rebound driven by a confluence of positive catalysts including a major investment bank upgrade and compelling clinical data readouts.

Morgan Stanley recently raised its target price on the company to 93 HKD and upgraded its rating to Overweight. Meanwhile, CLSA maintained its Outperform rating with a target price of 116.9 HKD. These bullish institutional endorsements follow the company's oral presentation at the 2026 World Conference on Lung Cancer on September 14, where updated Phase II data for LBL-024 (Opamtistomig) in combination with chemotherapy as first-line treatment for NSCLC showed an overall ORR of 71.0%, with non-squamous PD-L1-positive patients achieving an ORR of 81.8% and a DCR of 100%. The safety profile remained favorable and consistent with PD-L1 monotherapy combinations. The company is actively advancing Phase III clinical trial planning for first-line NSCLC treatment.

Within the Biotechnology sector, overall sentiment was positive. Among individual stocks, IMPACT THERAP-B up 27.86%, AKESO up 6.46%, INNOVENT BIO up 5.69%, BEONE MEDICINES up 1.98%, GENFLEET-B down 2.08%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)